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Abstract
Aims: Change in weight, HbA1c, lipids, blood pressure and cardiometabolic events 
over time is variable in individuals with type 2 diabetes. We hypothesised that people 
with a genetic predisposition to a more favourable adiposity distribution could have a 
less severe clinical course/progression.
Methods: We involved people with type 2 diabetes from two UK- based cohorts: 
11,914 individuals with GP follow- up data from the UK Biobank and 723 from 
Salford. We generated a ‘favourable adiposity’ genetic score and conducted cross- 
sectional and longitudinal studies to test its association with weight, BMI, lipids, 
blood pressure, medication use and risk of myocardial infarction and stroke using 15 
follow- up time points with 1- year intervals.
Results: The ‘favourable adiposity’ genetic score was cross- sectionally associated 
with higher weight (effect size per 1 standard deviation higher genetic score: 0.91 kg 
[0.59,1.23]) and BMI (0.30  kg/m2 [0.19,0.40]), but higher high- density lipoprotein 
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1 |  INTRODUCTION
Changes in weight, glycated haemoglobin (HbA1c), lipids 
and blood pressure over time display significant variabil-
ity across individuals with type 2 diabetes, with many and 
varied determinants including genetic, environmental and 
lifestyle factors. Weight gain in type 2 diabetes is asso-
ciated with multiple adverse consequences.1 Furthermore, 
long- term follow- up studies have clearly shown a direct 
relation between the levels of blood pressure, glucose and 
low- density lipoprotein cholesterol (LDL), and the compli-
cations of diabetes.2,3
The United Kingdom Prospective Diabetes Study 
(UKPDS) demonstrated the unequivocal benefit of inten-
sive treatment of dyslipidaemia and hypertension in terms 
of reducing cardiovascular event rate and mortality rate.4 If 
individuals who are more likely to develop diabetes compli-
cations can be identified early, both lifestyle advice and phar-
macotherapy can be targeted appropriately. This could make 
a very significant difference to outcomes for individuals with 
type 2 diabetes.
Previous studies have identified genetic variants where 
one allele is associated with higher adiposity but a healthier 
metabolic profile and lower risk of type 2 diabetes, heart 
disease and hypertension in the general population.5– 7 
These variants were named ‘favourable adiposity’ due to 
their paradoxical associations with adiposity and risk of 
disease. The ‘favourable adiposity’ variants confer a fa-
vourable metabolic profile even in those individuals with 
a higher body mass index (BMI).5 MRI scans of abdominal 
fat distribution have revealed that people with more favour-
able alleles are able to store more of the extra fat subcuta-
neously leading to less ectopic liver fat which results in a 
favourable metabolic profile despite higher adiposity.5 The 
role of ‘favourable adiposity’ genetic variants on glycaemic 
control and metabolic profile of people who already have 
type 2 diabetes is not clear.
In this study, we aimed to determine whether individuals 
with type 2 diabetes who have higher genetic predisposition 
to ‘favourable adiposity’ have a better glycaemic control, 
healthier lipid profile, lower blood pressure and lower risk 
of cardiovascular events over time. We generated a genetic 
score for ‘favourable adiposity’ and investigated its associ-
ation with the above cardiometabolic outcomes both cross- 
sectionally and longitudinally.
(0.02 mmol/L [0.01,0.02]) and lower triglycerides (−0.04 mmol/L [−0.07, −0.02]) in the 
UK Biobank at baseline, and this pattern of association was consistent across follow- up.
There was a trend for participants with higher ‘favourable adiposity’ genetic score to 
have lower risk of myocardial infarction and/or stroke (odds ratio 0.79 [0.62, 1.00]) 
compared to those with lower score. A one standard deviation higher score was associ-
ated with lower odds of using lipid- lowering (0.91 [0.86, 0.97]) and anti- hypertensive 
medication (0.95 [0.91, 0.99]).
Conclusions: In individuals with type 2 diabetes, having more ‘favourable adiposity’ 
alleles is associated with a marginally better lipid profile long- term and having lower 
odds of requiring lipid- lowering or anti- hypertensive medication in spite of relatively 
higher adiposity.
K E Y W O R D S
BMI, ectopic fat, favourable adiposity genetic score, HbA1c, metabolic profile, myocardial 
infarction, stroke, type 2 diabetes
Whats’ New?
• Recently, ‘favourable adiposity’ genetic variants 
associated with higher adiposity but better meta-
bolic profile have been identified in the general 
population.
• We show that a ‘favourable adiposity’ genetic 
score is associated with higher weight but a 
healthier lipid profile in people with type 2 diabe-
tes, and lower odds of requiring lipid- lowering or 
anti- hypertensive medication during the course of 
their disease.
• In the future, stratifying people into those with 
and without favourable adiposity might po-
tentially allow for both lifestyle management 
and pharmacotherapy to be targeted appropri-
ately to reduce metabolic complications and 
co- morbidities.
   | 3 of 11HEALD Et AL.
2 |  METHODS
2.1 | Study participants
We used two independent UK- based cohorts of people with 
type 2 diabetes: (i) The Salford Diabetes Cohort 8 and (ii) a 
subset of the UK Biobank study participants9 who were iden-
tified as having type 2 diabetes.
The analysis reported falls within the remit of the UK 
Biobank Ethical permission (Project Number ‘9072’ & 
‘9055’) and the Salford Cohort Ethics Approval (IRAS ethics 
committee reference number: 128954).
2.1.1 | UK Biobank
More than 500,000 individuals aged 37– 73  years were 
recruited between 2006 and 2010 from across the UK 
as described in detail elsewhere.9 We identified 12,787 
European type 2 diabetes cases in the UK Biobank using 
collated general practitioner (GP) records as those not 
coded as having non- type 2 (e.g. monogenic, gestational) 
types of diabetes and either (a) any two of the following 
criteria were met: (1) quality and outcome framework 
(QOF) diagnosis codes for diabetes provided by the NHS 
in GP record data, (2) HbA1c >= 48 mmol/mol (6.5%) and 
(3) a prescription for glucose- lowering medication, or (b) 
prescriptions were given for two or more different classes 
of glucose- lowering medication. We further restricted this 
to those with at least a 1- year gap from diagnosis with-
out requiring insulin (n = 422 were excluded) and age at 
diagnosis >35  years (suggested by the Royal College of 
General Practitioners in their review for classification of 
diabetes in England10; (n = 487 were excluded)), to limit 
the numbers of individuals with slow- progressing autoim-
mune diabetes or monogenic forms. This resulted in 11,914 
individuals with type 2 diabetes who also had genetic data. 
Age of diagnosis was set as the lowest age recorded in GP 
records, hospital episode statistics (HES) records and self- 
reported at the interview, altering the GP- recorded age of 
diagnosis for 338 individuals.
Details of change in weight, BMI, HbA1c, lipids and blood 
pressure for 15 time points with 1- year intervals were ob-
tained from the GP records, where available, using only the 
measurements taken after diagnosis of diabetes. Records of 
events and prescriptions for medications including glucose- 
lowering medication, lipid- lowering medication, antihyper-
tensive medication, myocardial infarction and stroke after the 
diagnosis of diabetes were taken from the UK Biobank as-
sessment centre and collated GP records, as well as HES re-
cords for myocardial infarction and stroke. Date of first event 
for myocardial infarction and stroke post- diabetes diagnosis 
were recorded.
The codes, and their descriptions, used to extract these 
measures from the UK Biobank are provided in the supple-
mentary method.
2.1.2 | Salford diabetes Cohort
The Salford prospective diabetes study is a cohort of individ-
uals (94% Europeans) aged 37– 88 years, nearly all with type 
2 diabetes, established in 2002 and described in more details 
elsewhere.8 Individuals were recruited consecutively from 
outpatient clinics and GP surgeries. We excluded individuals 
who have had bariatric surgery (n = 6), were diagnosed with 
type 2 diabetes aged under 36 (n = 143), had no recorded 
age of diagnosis (n = 28), were aged under 36 at baseline 
(n = 45) and individuals with one- off unusual weight read-
ings (n = 3).
Details of change in weight, BMI, HbA1c, lipids and 
blood pressure for 15 time points with 1- year intervals were 
obtained from collated GP electronic health records, using 
individual patient identifiers. We included data on glucose- 
lowering medications, lipid- lowering medications, antihy-
pertensive medications, myocardial infarction and stroke 
post- diabetes diagnosis.
2.2 | ‘Favourable adiposity’ genetic score
For the UK Biobank cohort, genotyping quality control was 
conducted by the UK Biobank itself.11 We used the index 
bgen program to extract SNP dosages.12 In the Salford study, 
we extracted DNA from 844 individuals from blood using 
the phenol/chloroform technique.13 Extracted samples were 
sent to LGC (https://www.biose archt ech.com) for genotyp-
ing using KASP assays. We excluded variants if the call rate 
<95% and the Hardy– Weinberg disequilibrium p < 0.01.
We constructed the genetic score for favourable adipos-
ity by calculating the number of favourable adiposity alleles 
carried by each individual (unweighted) across 14 genetic 
variants previously identified by Ji et al. (2019) (Table S1).5 
We used an unweighted genetic risk score as employed and 
recommended by Ji et al. (2019) 5 and also because we did 
not want to add the additional layer of complexity of effect 
size, in what was essentially an exploratory study.
2.3 | Statistical analysis
We studied the association between the ‘favourable adipos-
ity’ genetic score and the traits of interest cross- sectionally, 
using data from time point zero, and longitudinally, using 
data from all 15 time points. We corrected LDL and total 
cholesterol for lipid- lowering medication. We defined the 
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corrected measures as measured LDL/0.7 and total choles-
terol/0.8 for those on lipid medication.14 For any trait of in-
terest, any unresolvable outliers were identified and excluded 
prior to the analysis.
Linear regression models were used to evaluate the as-
sociation between the ‘favourable adiposity’ genetic score 
and the continuous outcomes, and logistic regression models 
were used for binary events.
In all the analyses, we used age in years at baseline, sex, 
genotyping platform and the first four ancestry principal 
components, where available, as covariates in the model. For 
the logistic regression models against myocardial infarction 
and stroke, we also adjusted for lipid and glucose- lowering 
medication and anti- hypertensive treatment. For the longitu-
dinal analyses, we additionally corrected for years from the 
start of the study.
Myocardial infarction and stroke were defined as binary 
events by their occurrence. Subsequent death from either 
event or other causes was not included in the analysis. Missing 
data, including event status (resulting from loss of follow- up 
or dropout), were not imputed. Medication use was defined 
as a prescription issued after diabetes diagnosis. Medication 
adjusted for in logistic models and lipid medication used in 
cholesterol corrections was defined as a prescription issued 
within 6 months before the event and the start of the study, 
respectively, in the UK Biobank (using the codes given in the 
supplementary method) as this time interval suggests medi-
cation use at the time of interest. In the case of no event, the 
time of the last recorded GP visit or interview was imputed 
as the time of the event. In the Salford cohort, medication use 
was defined as medication reported at the start of the study.
For longitudinal analyses, we tested an interaction be-
tween the genetic score and change in repeated measures over 
time. We used mixed- effects regression models that incorpo-
rated the year of measurement. In the UK Biobank, where 
measures at different time points were available with differ-
ing intervals, we corrected the statistical models for the exact 
age at the measurements to be consistent with the Salford 
study. The linear mixed- effects model for the Salford cohort 
is given by:
where i = 1,…,723 are the individuals, j = 0,…,15 are the re-
peated measures and εi is the random error. The interaction 
term β5 is our parameter of interest in the longitudinal analyses 
to test whether an increase/decrease in any trait over time is 
associated with the genetic score. All statistical analyses were 
conducted using R software.9
To group individuals into high and low genetic score 
for ‘favourable adiposity’, we calculated the median of the 
genetic score in the whole UK Biobank to be 12. We then 
grouped the individuals in each cohort into those (i) with a 
higher genetic score (≥12 alleles) and (ii) a lower score (<12 
alleles) (Figure S1), and compared these two groups in terms 
of their average outcomes over integer time points (rounding 
GP record time points down to the nearest year for the UK 
Biobank). We compared these groups using a paired t- test to 
test the null hypothesis that the mean readings for each time 
point are equal across the two groups.
We conducted random- effects inverse variance- weighted 
meta- analysis for each of the above analyses to combine the 
results of both the Salford and the UK Biobank cohorts. We 
performed gender- stratified analyses to investigate the effect 
of sex.
3 |  RESULTS
The mean and standard deviation of all the measures for both 
cohorts are given in Tables S2 and S3. There was a difference 
in age and time of measurements between the two cohorts, 
likely due to the narrower UK Biobank age range and the in-
creased likelihood of dropout in GP records compared to the 
Salford study (Table S4). The median ‘favourable adiposity’ 
genetic score was 11 for both cohorts.
For the UK Biobank cohort, the counts of events and 
prescriptions were as follows: glucose- lowering medication 
(9644 treated and 2269 diet- only treatment), lipid- lowering 
medication (10,622 treated and 1291 not on lipid- lowering 
medication), antihypertensive medication (9351 treated and 
2562 not on antihypertensive medication), myocardial in-
farction (1219 events and 10,523 no events) and stroke (1013 
events and 10,770 no events). For the Salford cohort, the 
counts of events and prescriptions were as follows: glucose- 
lowering medication (586 treated and 137 diet- only treat-
ment), lipid- lowering medication (639 treated and 84 not 
on lipid- lowering medication), antihypertensive medication 
(638 treated and 85 not on antihypertensive medication), 
myocardial infarction (133 events and 545 no events) and 
stroke (82 events and 614 no events).
Our linear regression models passed the diagnostic checks 
(Figure S2), with some deviation in the UK Biobank Q– Q 
plot that can be overlooked due to the Central Limit Theorem. 
The parameter estimates of the cross- sectional model and 
Equation 1 for the two cohorts are given in Tables S5 and S6 
respectively.
A one standard deviation (SD) higher ‘favourable adipos-
ity’ genetic score was associated with a 910 g higher weight 
(p = 2 × 10−8) and 0.30 kg/m2 higher BMI (p = 4 × 10−8) 
but a favourable metabolic profile, including higher HDL 
(p = 8 × 10−10) and lower triglycerides (p = 2 × 10−5), as well 
as lower systolic blood pressure (p = .02), in the UK Biobank 
study. However, these associations were not apparent in the 
meta- analysis with the smaller Salford study (Table 1). The 
(1)
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lack of association in the Salford study is likely the result of 
the significant difference in age and other participant char-
acteristics between the two cohorts and more importantly, 
the application of intense weight management programmes 
in the Salford study. We did not detect any cross- sectional 
association with HbA1c, total cholesterol, LDL and diastolic 
blood pressure and no sex- specific association (Table S7).
In the UK Biobank cohort, after capping the length of 
follow- up at 15  years, the mean duration of follow- up was 
8.0 ± 5.4 years. Overall mean decrease in weight was 2.6 kg 
(95% confidence interval [CI] 2.8, 2.5). However, 32% of in-
dividuals increased their weight over the follow- up period. 
There was a detectable decrease in HbA1c at 2.90  mmol/
mol [3.23, 2.57] (0.27% [0.30, 0.23]); 43% of individuals in-
creased their HbA1c over the repeat measures. HDL increased 
over time by 0.03 mmol/L [0.03, 0.04], with 36% showing 
a drop; while both triglycerides and LDL showed decreases 
of 0.23 mmol/L [0.25, 0.21] and 0.41 mmol/L [0.43, 0.39], 
respectively, with 35% and 25% showing rises in these traits. 
There was an increase in LDL levels in the last few visits 
(Figure 1), which could be the result of a drop in the sam-
ple size (Table S2). Mean decrease in systolic blood pressure 
was 5.9 mmHg [6.2, 5.5], with 34% of people showing an 
increase over time.
In the Salford cohort, the mean duration of follow- up was 
11.5 ± 2.4 years. Overall mean decrease in weight was 4 kg 
[5, 3]; however, 36% of individuals increased their weight 
over the follow- up period. There was also a decrease in HbA1c 
at 3.97 mmol/mol [5.58, 2.35] (0.36% [0.51, 0.22]) and 40% 
of individuals increased their HbA1c over the repeat mea-
sures. Change in HDL was not significant at 0.01 mmol/L 
[−0.01, 0.04], with 49% of participants reducing their HDL 
over time. Triglycerides, LDL and systolic blood pressure all 
reduced over time by 0.44 mmol/L [0.52, 0.36], 0.67 mmol/L 
[0.75, 0.60], and 4.9  mmHg [6.7, 3.1], respectively, with 
30%, 19% and 38% instead showing increases for each trait.
A higher ‘favourable adiposity’ genetic score was associ-
ated with a greater increase in BMI (p = .03) over 15 years 
on average, in the meta- analysis of the UK Biobank and the 
Salford study. There was no evidence (at p <  .05) of inter-
action between the ‘favourable adiposity’ genetic score and 
change in weight, HbA1c, triglycerides, total cholesterol, 
HDL, LDL or blood pressure over the follow- up period 
(Table 2) or any sex- specific association (Table S8).
In the UK Biobank, those in the higher ‘favourable adipos-
ity’ genetic score group had small, but consistent and statisti-
cally significant differences from the lower genetic score group 
(Figure 1). These included higher weight (p = 3.7 × 10−10) and 
higher BMI (p = 5.6 × 10−9) across multiple time points, but 
higher HDL (p = .002), lower triglycerides (p = 1.4 × 10−8), 
lower total cholesterol (p  =  9.1  ×  10−5) and lower HbA1c 
(p  =  .02). In Salford, we observed smaller differences with 
larger confidence intervals which may relate to the relatively 
small numbers of individuals in the higher genetic score group 
(n = 245) and the application of intense weight management 
programmes in that area of the UK (Figure S1).
In the meta- analysis of the UK Biobank and Salford, 
we did not detect any association between the continuous 
T A B L E  1  Cross- sectional association between ‘favourable adiposity’ genetic score and weight and metabolic profile of individuals with type 2 
diabetes, using baseline measurements
Outcome
UK Biobank GP record Salford Meta- analysis
Beta 95% CI P N Beta 95% CI P N Beta 95% CI P
Weight (kg) .91 (0.59,1.23) 2 × 10−8 11,498 −.32 (−1.81,1.17) .67 421 .52 (−0.61,1.65) .37
BMI (kg/m2) .30 (0.19,0.40) 4 × 10−8 11,492 −.06 (−0.57,0.45) .81 409 .21 (−0.09,0.51) .17
HbA1c (mmol/mol) .21 (−0.09,0.51) .18 11,638 2.01 (0.49,3.53) .01 425 .95 (−0.79,2.69) .29
HbA1c (%) .02 (−0.01,0.05) .18 11,638 .18 (0.05,0.32) .01 425 .09 (−0.07,0.25) .29
HDL (mmol/L) .02 (0.01,0.02) 8 × 10−10 11,224 −.01 (−0.04,0.03) .69 370 .01 (−0.01,0.03) .29
Triglycerides 
(mmol/L)
−.04 (−0.07,−0.02) 2 × 10−5 10,910 .04 (−0.07,0.15) .45 369 −.02 (−0.10,0.06) .65
Total cholesterol* 
(mmol/L)
.00 (−0.02,0.02) .97 11,495 −.03 (−0.14,0.08) .57 411 .00 (−0.02,0.02) .88
LDL* (mmol/L) −.02 (−0.04,0.00) .08 8,533 −.01 (−0.13,0.12) .92 357 −.02 (−0.04,0.00) .08
Systolic blood 
pressure (mmHg)
−.41 (−0.77, −0.06) .02 11,576 1.52 (−0.11,3.14) .07 434 .38 (−1.48,2.25) .69
Diastolic blood 
pressure (mmHg)
.10 (−0.13,0.34) .39 11,576 .41 (−0.61,1.42) .43 434 .12 (−0.11,0.35) .31
Beta is the change in trait per one SD (standard deviation) higher ‘favourable adiposity’ genetic score.
Abbreviations: 95% CI: 95% confidence interval; BMI: body mass index, HbA1c: glycated haemoglobin; HDL: high- density lipoprotein; LDL: low- density lipoprotein. 
*Total cholesterol and LDL are corrected for lipid medication; N: number of samples; P: p value.
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‘favourable adiposity’ genetic score and risk of myocardial 
infarction or stroke. However, for those in a higher ‘fa-
vourable adiposity’ genetic score group, there was a trend 
towards a lower risk of myocardial infarction and/or stroke 
(odds ratio (OR) 0.79 [0.62, 1.00], p  =  .047) compared 
to the lower genetic score group, when using a binary ge-
netic score group variable. A one SD higher genetic score 
was associated with lower odds of taking lipid- lowering 
medication (OR 0.91 [0.86, 0.97], p  =  .002) and anti- 
hypertensive medication (OR 0.95 [0.91,0.99], p  =  .01) 
(Table 3).
4 |  DISCUSSION
Our study suggests that having more ‘favourable adiposity’ 
alleles is associated with maintaining a marginally better 
lipid profile and blood pressure in spite of relatively higher 
adiposity in people with type 2 diabetes. This favourable ef-
fect lasts for several years after diagnosis.
The identification of ‘favourable adiposity’ genetic vari-
ants was originally carried out in population- based cohorts.5 
In a general population, these alleles are associated with 
higher adiposity, but a favourable cardiometabolic profile. 
Our study extends this finding to people with type 2 diabe-
tes by showing that even in those who already have type 2 
diabetes, these alleles are associated with higher weight but 
higher HDL, lower triglycerides and lower systolic blood 
pressure.
Our longitudinal study revealed that those who have a 
higher ‘favourable adiposity’ genetic score do not change 
their weight over time on average, but they have constantly 
higher weight during their course of disease compared to 
those with a lower genetic score. Furthermore, the longitu-
dinal results show that having a higher genetic score does 
not help with glycaemic control but it helps with maintain-
ing a relatively good lipid profile by having higher HDL, 
lower triglycerides and lower cholesterol. However, while 
the general associations with the ‘favourable adiposity’ 
alleles were confirmed in the UK Biobank, they are very 
weak in terms of the changes in lipids, and as such are un-
likely to be useful for clinical decision- making at the pres-
ent time.
We have shown that having a higher ‘favourable adi-
posity’ genetic score is associated with lower odds of tak-
ing lipid- lowering or anti- hypertensive medication after 
diabetes diagnosis, and that for those who have a higher 
‘favourable adiposity’ genetic score (≥12 alleles) there is a 
F I G U R E  1  The genetic effect of ‘favourable adiposity’ on change in (a) weight, (b) body mass index (BMI), (c) glycated haemoglobin 
(HbA1c), (d) triglycerides, (e) high- density lipoprotein (HDL), (f) total cholesterol, (g) low- density lipoprotein (LDL), (h) systolic blood pressure 
and (i) diastolic blood pressure from 15 follow- up time points with 1- year intervals from the UK Biobank. We grouped the cohort into (i) 
individuals who had 50% or more of the ‘favourable adiposity’ alleles (blue lines) and (ii) individuals who had less than 50% of the alleles (red 
lines). *Total cholesterol and LDL are corrected for lipid medication. p values are from a paired t- test examining the null hypothesis that the means 
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trend towards a reduced risk of myocardial infarction and/
or stroke compared to those with a lower genetic score. 
Both of these may be the result of a beneficial lipid and 
blood- pressure profile prior to the diagnosis of diabe-
tes and during the course of the disease. We do not have 
specific information on the drivers for statin prescribing. 
However, it may well be the case that as in the general pop-
ulation, the people who receive statin treatment are those 
with a greater cardiovascular risk and so these individuals 
will intrinsically have a higher cardiovascular event rate 
than those not prescribed statin therapy.15 This could re-
flect that people with a higher genetic score are assessed 
to be at lower risk by the cardiovascular risk assessment 
undertaken in primary care. It has been previously reported 
that the likelihood of a statin being prescribed was not nec-
essarily related to the lipid profile itself in people with di-
abetes.16 Furthermore, if the ‘favourable adiposity’ genetic 
score is associated with increased case fatality from myo-
cardial infarction, this estimate would be biased towards a 
larger effect size. A larger amount of prospective data will 
be needed to validate this finding.
Among many possible mechanisms, the local and sys-
temic effect of ectopic fat is postulated to explain the higher 
risk of hypertension, dyslipidaemia, heart disease and stroke 
in people with type 2 diabetes.17– 23 The mechanism by which 
the ‘favourable adiposity’ genetic score is protecting against 
risk of disease is likely to be through its association with the 
ability to store excess fat more subcutaneously which sub-
sequently prevents ectopic lipid accumulation.5 This could 
explain why individuals who have a higher ‘favourable ad-
iposity’ genetic score have lower blood pressure, and lower 
risk of myocardial infarction or stroke in spite of relatively 
higher adiposity.
Our study is unique as it is among few studies using ge-
netic scores within people with diabetes. Previous studies 
consist of those which used genetic scores of type 1 diabe-
tes to discriminate type 1 from type 2 or monogenic forms 
of disease24,25 or to predict progression to insulin therapy 
in clinically diagnosed people with type 2 diabetes26 or to 
delineate risk genotypes for type 2 diabetes.27,28 Type 2 
diabetes is a complex and common condition. Over time, 
as many as 45% of individuals develop dyslipidaemia and 
35% develop high blood pressure but the proportions are 
highly dependent on the intensity of monitoring and of 
treatment and treatment concordance.4 Identifying ways 
of stratifying cardiometabolic risk in people with type 2 
diabetes could allow for both lifestyle management and 
pharmacotherapy to be targeted appropriately to reduce 
the metabolic complications and co- morbidities as time 
goes forward. Genetics of favourable adiposity may aid 
this process but further research is required to test its gen-
eralisability and predictive value alongside known cardio-
vascular genetic variants.
4.1 | Study strengths and limitations
The strength of our study is both a cross- sectional and 
long- term follow- up design with comprehensive metabolic 
characterisation that can be collected through primary care 
follow- up. We had follow- up data over 15 years for both the 
UK Biobank and Salford participants; two independently 
sampled groups. It is expected that as time goes on, more 
follow- up data will become available. However, the pheno-
typic follow- up data are subject to the inaccuracies of data 
collection in a real- world healthcare setting.
Our study is subject to some bias mainly due to the med-
ication taken by our participating individuals. It is the case 
that those with a higher ‘favourable adiposity’ genetic score 
may more often result in being overweight or obese and if 
diabetes is diagnosed, these individuals may more often re-
ceive weight- lowering treatment, such as GLP- 1 analogues. 
These treatments would counteract the further increase in 
weight that would have been observed with a weight- neutral 
treatment; while also in the case of a GLP- 1 analogue would 
reduce cardiovascular risk. Furthermore, many treatments 
that have been utilised for type 2 diabetes in recent years 
have modulating effects on adipose tissue distribution. These 
medications are continually titrated to ‘treat to target’ in peo-
ple with type 2 diabetes in the UK clinical setting. In other 
words, the sometimes frequent changes in medication, some 
of which such as sulphonylureas, thiazolidenediones (glita-
zones), sodium glucose- like transport- 2 inhibitors (SGLT- 
2is), glucagon- like peptide- 1 (GLP- 1) agonists and insulin 
can have a profound effect on weight trajectory and blood 
glucose levels.29
The other bias which could have affected our results is 
collider bias (or index event bias).30 A collider is a trait (here 
type 2 diabetes status) that is influenced by two other traits 
of interest (e.g. here genetics of ‘favourable adiposity’ and 
triglycerides), which can induce a false association or reverse 
the sign of true associations. In this study, we focused on in-
dividuals with type 2 diabetes. People with a higher ‘favour-
able adiposity’ genetic score in our study probably had worse 
insulin secretion or had other risk factors to develop diabetes 
in the first place. However, there is no evidence to suggest 
lower insulin secretion is associated with higher BMI and a 
favourable metabolic profile. Furthermore, there was no as-
sociation between the ‘favourable adiposity’ genetic score 
and HbA1c. In fact, in the UK Biobank where we had more 
data on HbA1c, we detected a reverse association between the 
‘favourable adiposity’ genetic score and HbA1c. Finally, the 
association between the ‘favourable adiposity’ genetic score 
and higher BMI and a favourable lipid profile was established 
in population- based cohorts.5
One further limitation of the UK Biobank GP records data 
is that loss of follow- up increases over time, as individuals 
are likely to make fewer visits to the GP as the time from 
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type 2 diabetes diagnosis increases, leading to much smaller 
sample sizes later on.
5 |  CONCLUSION
We found that the genetics of ‘favourable adiposity’ is as-
sociated with higher weight but a more favourable lipid 
profile and lower blood pressure in people already diag-
nosed with type 2 diabetes in the UK Biobank and that this 
favourable effect is maintained over time. These observed 
effects are independent of glycaemic control. However, the 
magnitude of the effects are small and as such are unlikely 
to be useful for clinical decision- making at present. Future 
studies may determine whether a genetic predisposition to 
favourable adiposity in people with type 2 diabetes could 
improve the prognosis of the disease in terms of less car-
diovascular events.
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